When can an applicant with acute gout be considered for a fit assessment?

A fit assessment may be considered once the applicant is asymptomatic, after cessation of treatment, or when the condition is stabilised on anti-hyperuricaemic therapy.

What is required for a fit assessment of an applicant with diabetes mellitus who does not require medication?

Subject to good control of blood sugar with no hypoglycaemic episodes, applicants with diabetes mellitus not requiring medication may be assessed as fit.

AMC1 MED.B.025 Metabolic and endocrine systems

Q: Under what conditions can an applicant with a metabolic, nutritional, or endocrine dysfunction be assessed as fit?

An applicant may be assessed as fit if the condition is asymptomatic, clinically compensated and stable with or without replacement therapy, and regularly reviewed by an appropriate specialist.

Q: What is the minimum Body Mass Index threshold that triggers a specific risk assessment for obesity in aviation medical certification?

A Body Mass Index of 35 or greater triggers the requirement for a risk assessment, including evaluation of the cardiovascular system and the possibility of sleep apnoea, before a fit assessment can be considered.

Q: For applicants with Addison's disease, what condition must be met for a fit assessment with an OML to be considered?

A fit assessment with an OML may be considered provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s).

Q: How can an applicant with abnormal glucose metabolism be assessed as fit if they have impaired glucose tolerance without diabetic pathology?

A fit assessment may be considered if impaired glucose tolerance without diabetic pathology is fully controlled by diet and regularly reviewed.

Q: Which type of antidiabetic medication may be acceptable for a fit assessment with an OML?

The use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable for a fit assessment with an OML.

Navigate / EASA

Ask question Discover more Add to collection

AMC1 MED.B.025 Metabolic and endocrine systems

ED Decision 2019/002/R

(a) Metabolic, nutritional or endocrine dysfunction

Applicants with metabolic, nutritional or endocrine dysfunction may be assessed as fit if the condition is asymptomatic, clinically compensated and stable with or without replacement therapy, and regularly reviewed by an appropriate specialist.

(b) Obesity

Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory.

Applicants with Addison’s disease should be assessed as unfit. A fit assessment with an OML may be considered, provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s).

(d) Gout

Applicants with acute gout should be assessed as unfit. A fit assessment may be considered once asymptomatic, after cessation of treatment or the condition is stabilised on anti-hyperuricaemic therapy.

(e) Thyroid dysfunction

Applicants with hyperthyroidism or hypothyroidism should be assessed as unfit. A fit assessment may be considered when a stable euthyroid state is attained.

(f) Abnormal glucose metabolism

Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance without diabetic pathology is fully controlled by diet and regularly reviewed.

(g) Diabetes mellitus

Subject to good control of blood sugar with no hypoglycaemic episodes:

(1) applicants with diabetes mellitus not requiring medication may be assessed as fit;

(2) the use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable for a fit assessment with an OML.

Details

Source-Title: AMC1 MED.B.025 Metabolic and endocrine systems View latest amendments

Erulesid: ERULES-1963177438-11253 Compare versions

Domain: Aircrew

Applicabilitydate: 30 January, 2019

Entryintoforcedate: 29 January, 2019

Regulatorysource: ED Decision 2019/002/R Navigate

Regulatorysubject: Part-MED

Typeofcontent: AMC to IR (Acceptable means of compliance to implementing rule)

Parentir: MED.B.025 Metabolic and Endocrine Systems

Origin: EASA

Category: EAR